Dr. Timothy S. Chang's lab at UCLA focuses on improving the identification of Alzheimer's disease (AD), especially in underrepresented groups such as Hispanic/Latino and African American populations. The lab uses electronic health records and advanced machine learning techniques to analyze disease trajectories and genetic data. By understanding how different diseases accumulate over time, the team aims to find individuals with undiagnosed AD and reduce health disparities in diagnosis and treatment.

Dr. John Cirrito's lab at Washington University focuses on understanding how synaptic activity in the brain impacts the formation and aggregation of amyloid-beta, a critical component involved in Alzheimer's disease. By using specialized technologies to monitor these processes in real-time, the lab aims to determine how different types of neurons contribute to amyloid-beta production and aggregation, potentially leading to new insights for developing therapies against Alzheimer's disease.

Dr. Ying Leong Chan's lab at the University of Massachusetts focuses on understanding how exposure to heavy metals, like cadmium, influences Alzheimer's disease. They use innovative human-derived brain models to explore how genetic factors and viral infections, specifically the herpes simplex virus, might interact to accelerate Alzheimer's-related changes in the brain. The work aims to uncover new insights into the disease's causes and develop potential treatment approaches.

Dr. Riqiang Yan's lab focuses on understanding the role of the enzyme BACE1 in Alzheimer's disease, particularly how inhibiting this enzyme in glial cells might help reduce harmful amyloid and tau pathologies in the brain. The lab conducts experiments using transgenic mouse models to explore innovative treatments that enhance the immune response of microglia, which are crucial for clearing out these toxic substances. The ultimate goal is to develop safer therapeutic strategies for Alzheimer's patients.

Dr. Katrin Andreasson's lab at Stanford University focuses on understanding the roles of immune cells in cognitive decline related to aging and Alzheimer's disease. The research explores how signaling pathways, particularly involving inflammatory signals like prostaglandin E2 (PGE2), affect the function of both peripheral myeloid cells and brain microglia. By investigating these mechanisms, the lab aims to identify potential therapies that could improve cognitive function and mitigate age-related decline.

The lab led by Dr. Josef Anrather at Weill Medical College of Cornell University focuses on understanding how environmental factors trigger Multiple Sclerosis (MS) and other CNS autoimmune diseases. They investigate the role of specific toxins, particularly Clostridium perfringens epsilon toxin and Bordetella pertussis toxin, in compromising the protective barriers of the central nervous system and leading to autoimmunity. The goal is to identify potential molecular targets for new diagnostic and therapeutic strategies to combat MS.

Dr. Leonardo F. Bonilha's lab focuses on understanding and improving treatment for aphasia, a language disorder resulting from stroke. The lab is exploring innovative techniques such as transcranial direct current stimulation (tDCS) to enhance traditional speech therapy outcomes. They also study the effects of brain aging and cardiovascular health on aphasia severity, aiming to personalize therapies for stroke survivors.

Dr. Bhooma Aravamuthan's lab at Washington University focuses on understanding and treating dystonia, a movement disorder that often affects children born prematurely. The research explores how injuries in the brain's cortex, specifically involving a type of neuron called parvalbumin-positive interneurons, contribute to dystonia. By using innovative mouse models, the lab aims to identify predictive markers of dystonia and develop potential new therapies targeting these cortical neurons to improve treatment outcomes.

Dr. Emanuela Argilli's research lab at UCSF focuses on understanding the genetic causes of agenesis of the corpus callosum (ACC), a brain condition linked to various neurodevelopmental disorders like autism, epilepsy, and intellectual disabilities. By studying genetic data from large population samples and engaging in cutting-edge genomic techniques, the lab aims to discover novel genes associated with ACC and explore their implications for brain function and potential treatments. Ultimately, this research could lead to better understanding and interventions for common developmental disorders affecting many individuals worldwide.

Dr. Amy Christine Arnold's lab at Penn State Hershey focuses on understanding the relationship between obesity and hypertension, particularly how a protective hormone called angiotensin-(1-7) can improve cardiovascular health in obese individuals. They explore both cellular mechanisms and clinical outcomes related to blood pressure and metabolic function to develop better therapies. This research is vital as obesity-related hypertension is a growing global health issue.

Dr. Andrew Aschenbrenner's lab focuses on improving cognitive monitoring for patients undergoing treatment for Alzheimer's disease. The team is developing a smartphone-based system to detect cognitive changes that may occur due to treatment side effects, specifically amyloid-related imaging abnormalities. This project aims to make cognitive assessments more accessible and less burdensome for patients, ultimately enhancing treatment safety and effectiveness.

Dr. Yongjie Yang's lab at Tufts University studies the role of glial cells in neurodevelopmental and neurodegenerative diseases. Specifically, they investigate how astrocytes, a type of glial cell, contribute to conditions like Fragile X Syndrome and Alzheimer's Disease. The research focuses on understanding the molecular mechanisms influencing behavior and immune responses in these diseases.

Dr. Chris G. Dulla's lab at Tufts University focuses on understanding how astrocytes, a type of brain cell, change as we age and in conditions like Alzheimer’s Disease (AD). The lab has identified a new type of astrocyte called atypical astrocytes (AtAs) that lose important functions, which might contribute to neurological issues. They are exploring how vascular health and blood-brain barrier integrity relate to these changes and how they affect overall brain function during aging and disease.

Dr. Allison Brashear's lab at the University at Buffalo focuses on studying the genetic mutations of the ATP1A3 gene, which can cause a variety of neurological disorders. By employing a mix of patient phenotyping and laboratory testing, the lab aims to understand the symptoms related to these mutations and find potential treatments. They explore how these mutations affect cellular functions and how existing drugs can be used to alleviate symptoms, ultimately hoping to broaden diagnosis and treatment options for affected individuals.

Dr. David Schneider's lab at NYU studies how the brain processes sounds we make ourselves, particularly in skills like speaking and making music. By using mice as model organisms, his team investigates how neural networks in the auditory cortex respond to sound and how they help us learn and correct our behaviors based on what we hear. This research enhances our understanding of the brain circuits involved in learning through auditory feedback.

Dr. Gregory Wu's lab at Washington University focuses on finding innovative immunotherapies for autoimmune diseases like multiple sclerosis. By utilizing advanced CAR-T cell technology, the research aims to specifically target and eliminate T cells that attack the nervous system without compromising the overall immune system. This could lead to more effective treatments for patients with chronic autoimmune conditions.

Dr. Naresha Saligrama's research lab at Washington University focuses on understanding the immune responses involved in autoimmune diseases, particularly multiple sclerosis (MS) and the roles of specific T cells. They investigate how certain immune T cell receptors react with both myelin and viral antigens, aiming to uncover the triggers of MS. Additionally, the lab explores the function of unique regulatory T cells that could provide insights for treating autoimmune conditions.

Dr. Jet M.J. Vonk's research lab at UCSF focuses on utilizing automated speech analysis to detect early signs of Alzheimer's disease (AD). The lab aims to develop and validate a speech profile that captures subtle language changes indicative of cognitive decline, especially in racially and ethnically diverse populations. By employing machine learning techniques on speech samples, the lab seeks to create a clinically viable tool for early diagnosis and monitoring of AD, bridging gaps in current diagnostic practices.

Dr. Matthew Rasband's lab at Baylor College of Medicine focuses on understanding the structure and function of axons, particularly how they communicate and maintain stability in the nervous system. They study the molecular mechanisms that govern axon health and integrity, especially in the context of diseases like bipolar disorder and other neuropsychiatric conditions. By using advanced genetic and imaging techniques, they aim to discover new therapies that could potentially repair or preserve axon function during injury or disease.

Martha W Bagnall's lab focuses on understanding how neuromodulators like dopamine and serotonin influence movement in zebrafish. By utilizing advanced imaging techniques and genetic tools, the lab explores how these chemicals affect spinal cord circuits to control locomotion during different behaviors. This research aims to uncover the mechanisms behind neuromodulatory action and its significance in motor control.